We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Siemens Healthineers

  Gold Provides customized electronic systems and advanced imaging, diagnostics, therapy, and healthcare IT solutions for th... read more Featured Products: More products

Download Mobile App





Siemens Secures New FDA Emergency Use Authorizations for Coronavirus Antibody Test

By LabMedica International staff writers
Posted on 11 Jun 2020
Print article
Image: COVID-19 Total Antibody Test and Molecular Test Kit (Photo courtesy of Siemens Healthineers)
Image: COVID-19 Total Antibody Test and Molecular Test Kit (Photo courtesy of Siemens Healthineers)
Siemens Healthineers (Erlangen, Germany) has been granted Emergency Use Authorizations (EUAs) by the US Food and Drug Administration (FDA) for its total antibody test to detect the presence of SARS-CoV-2 antibodies running on the company’s Dimension Vista and Dimension EXL analyzers.

The FDA has granted EUA to Siemens’ Dimension Vista SARS-CoV-2 total antibody assay and Dimension EXL SARS-CoV-2 total antibody assay in order to identify people with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Both the products are sandwich-based chemiluminescent immunoassays.

Siemens had been developing the total antibody assay for use on its Dimension analyzers as well as on the company’s Advia Centaur and Atellica analyzers. Siemens had secured two EUAs for its laboratory-based total antibody test in May – one for use on the company’s Advia Centaur XP and Advia Centaur XPT systems, and the second for use on its Atellica next-generation system.




Print article

Channels

Molecular Diagnostics

view channel
Image: The Chemagic 360 extracts DNA and uses transiently magnetized rods to attract the beads after binding to the nucleic acids (Photo courtesy of PerkinElmer).

Blood Group Locus Contributes to COVID-19 Severity Risk

There is considerable variation in disease behavior among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19).... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.